CCR5 Antagonism in HIV Infection: Current Concepts and Future Opportunities

Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention

(2011) Olga Latinovic et al.   AIDS

Reanalysis of Coreceptor Tropism in HIV-1-Infected Adults Using a Phenotypic Assay with Enhanced Sensitivity

(2011) T. J. Wilkin et al.   CLINICAL INFECTIOUS DISEASES

The Relationship of CCR5 Antagonists to CD4+ T-Cell Gain: A Meta-Regression of Recent Clinical Trials in Treatment-Experienced HIV-Infected Patients

(2011) Timothy J. Wilkin et al.   HIV CLINICAL TRIALS

Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1–Infected, Treatment-Experienced, CCR5 Antagonist–Naive Subjects

(2011) Jacob Lalezari et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Single and Multiple Dose Pharmacokinetics of Maraviroc in Saliva, Semen, and Rectal Tissue of Healthy HIV-Negative Men

(2011) Kevin C. Brown et al.   JOURNAL OF INFECTIOUS DISEASES

CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells

(2011) Olga Latinovic et al.   VIROLOGY

Hepatic safety and tolerability in the maraviroc clinical development program

(2010) Ayman Ayoub et al.   AIDS

Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

(2010) J. M. Jacobson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study

(2010) Juan Sierra-Madero et al.   HIV CLINICAL TRIALS

Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2

(2010) W David Hardy et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Three-Year Safety and Efficacy of Vicriviroc, a CCR5 Antagonist, in HIV-1–Infected Treatment-Experienced Patients

(2010) Timothy J Wilkin et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Antiretroviral Treatment of Adult HIV Infection

(2010) Melanie A. Thompson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection

(2010) David A. Cooper et al.   JOURNAL OF INFECTIOUS DISEASES

Protection of Rhesus Macaques from Vaginal Infection by Vaginally Delivered Maraviroc, an Inhibitor of HIV‐1 Entry via the CCR5 Co‐Receptor

(2010) Ronald S. Veazey et al.   JOURNAL OF INFECTIOUS DISEASES

Anti–HIV‐1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody

(2010) Jeffrey M. Jacobson et al.   JOURNAL OF INFECTIOUS DISEASES

Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment‐Experienced Subjects: 48‐Week Results of the VICTOR‐E1 Phase 2 Trial

(2010) Jamal Suleiman et al.   JOURNAL OF INFECTIOUS DISEASES

An Imidazopiperidine Series of CCR5 Antagonists for the Treatment of HIV: The Discovery ofN-{(1S)-1-(3-Fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798)

(2010) Paul A. Stupple et al.   JOURNAL OF MEDICINAL CHEMISTRY

Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients

(2010) Nicholas Funderburg et al.   PLoS One

Oral Pre-Exposure Prophylaxis by Anti-Retrovirals Raltegravir and Maraviroc Protects against HIV-1 Vaginal Transmission in a Humanized Mouse Model

(2010) C. Preston Neff et al.   PLoS One

Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals

(2009) Jessica L Long et al.   AIDS

Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy

(2009) Benoît Marin et al.   AIDS

Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136)

(2009) P Yeni et al.   HIV MEDICINE

Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women

(2009) Julie B Dumond et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Incidence of Non-AIDS-Defining Malignancies in HIV-Infected Versus Noninfected Patients in the HAART Era: Impact of Immunosuppression

(2009) Roger J Bedimo et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Response to Vicriviroc in Treatment‐Experienced Subjects, as Determined by an Enhanced‐Sensitivity Coreceptor Tropism Assay: Reanalysis of AIDS Clinical Trials Group A5211

(2009) Zhaohui Su et al.   JOURNAL OF INFECTIOUS DISEASES

A Double‐Blind, Placebo‐Controlled Trial of Maraviroc in Treatment‐Experienced Patients Infected with Non‐R5 HIV‐1

(2009) Michael Saag et al.   JOURNAL OF INFECTIOUS DISEASES

Tropism testing in the clinical management of HIV-1 infection

(2009) Nina H Lin et al.   Current Opinion in HIV and AIDS

Phase II Study of Vicriviroc versus Efavirenz (both with Zidovudine/Lamivudine) in Treatment‐Naive Subjects with HIV‐1 Infection

(2008) Raphael J. Landovitz et al.   JOURNAL OF INFECTIOUS DISEASES

Safety, Pharmacokinetics, and Antiviral Activity of HGS004, a Novel Fully Human IgG4 Monoclonal Antibody against CCR5, in HIV‐1–Infected Patients

(2008) Jacob Lalezari et al.   JOURNAL OF INFECTIOUS DISEASES

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

(2008) Gerd Fätkenheuer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

(2008) Roy M. Gulick et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

(2008) B. F. Keele et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA